Introduction to Extranodal Rosai-Dorfman Disease

Breast Rosai-Dorfman disease is an exceptionally rare extranodal presentation of a benign histiocytic disorder. While the disease typically manifests as massive, painless cervical lymphadenopathy, clinicians increasingly recognize extranodal involvement in approximately 40% of cases. Breast involvement remains particularly infrequent, often creating a diagnostic dilemma because it closely mimics primary breast carcinoma on clinical examination and routine imaging. Consequently, understanding the unique pathologic features of this entity is vital for preventing aggressive overtreatment.

Radiologic and Clinical Presentation

Patients with this condition generally present with firm, palpable breast masses that may be painless or slightly tender. In some instances, clinicians detect the lesion incidentally during imaging for unrelated concerns. Mammography and ultrasound frequently reveal irregular, spiculated, or ill-defined masses. Radiologists often categorize these findings as BI-RADS 4 or 5, which strongly suggests malignancy. Furthermore, PET/CT scans may show high FDG uptake, further complicating the differentiation from breast cancer or lymphoma.

Diagnostic Features of Breast Rosai-Dorfman Disease

Because imaging is often inconclusive, histopathologic evaluation serves as the gold standard for diagnosis. Microscopic examination typically shows a dense lymphoplasmacytic infiltrate and large, pale histiocytes. A hallmark feature known as emperipolesis, where histiocytes engulf intact lymphocytes or erythrocytes, is often present. Immunohistochemistry plays a critical role in confirmation. The diagnostic histiocytes characteristically express S100, CD68, and CD163. Conversely, they remain negative for CD1a, which helps distinguish the condition from Langerhans cell histiocytosis.

Management and Clinical Outcomes

Management strategies for breast Rosai-Dorfman disease vary based on the extent of the disease and patient symptoms. Many patients achieve excellent outcomes through surgical excision, which often provides both a definitive diagnosis and treatment. However, conservative management with close clinical and radiologic follow-up is an appropriate alternative for asymptomatic, biopsy-proven lesions. Most cases limited to the breast follow a benign course without systemic recurrence. Therefore, a multidisciplinary approach involving pathologists, radiologists, and surgeons ensures optimal patient care and prevents unnecessary radical procedures.

Frequently Asked Questions

Is breast Rosai-Dorfman disease cancerous?

No, it is a benign (non-cancerous) histiocytic disorder. However, it is significant because it mimics breast cancer on mammograms and ultrasounds, requiring a biopsy for a definitive diagnosis.

How do doctors treat this condition?

Treatment is individualized. Options include surgical excision of the mass or conservative observation with regular follow-up imaging, depending on the lesion's size and the patient's symptoms.

What is the hallmark of this disease under a microscope?

The hallmark is emperipolesis, a process where large histiocytes contain intact inflammatory cells within their cytoplasm. Specialized staining for the S100 protein also confirms the diagnosis.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.

References

Hernandez Guzman AR et al. Rosai-Dorfman Disease of the Breast: A Case Series and Review of the Literature. Int J Surg Pathol. 2026 May 04. doi: 10.1177/10668969261438513. PMID: 42081251.

Carstina D et al. Rosai–Dorfman Disease: Breast Involvement—Case Report and Literature Review. Medicina (Kaunas). 2021 Oct 27;57(11):1167. doi: 10.3390/medicina57111167.

Adejayan A et al. Rosai-Dorfman Disease of the Breast: Radiologic-Pathologic Correlation. Journal of Breast Imaging. 2025 Oct 28. doi: 10.1093/jbi/wbae057.